PTI - Proteostasis Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Proteostasis Therapeutics, Inc.

80 Guest Street
Suite 500
Boston, MA 02135
United States

Full Time Employees48

Key Executives

NameTitlePayExercisedYear Born
Ms. Meenu ChhabraPres, CEO & Director772.5kN/A1972
Dr. Benito MunozChief Scientific Officer477.27kN/A1962
Dr. Po-Shun LeeConsultant486.95kN/A1969
Mr. Eric D. LarsonPrincipal Financial Officer & Principal Accounting OfficerN/AN/A1970
Ms. Sheila Gilbride Wilson M.B.A.Chief Operating OfficerN/AN/A1958
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of various small molecule therapeutics to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing. The company's lead product candidates for the treatment of CF include PTI-801, a third generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.

Corporate Governance

Proteostasis Therapeutics, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.